Two Sigma Securities’s Altamira Therapeutics Ltd CYTO Stock Holding History

Two Sigma Securities’s Portfolio CYTO Stock Details CYTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-58	Closed	-$7K	–	3438
2022 Q3	$7K	Buy	+58	New	+$9.63K	﹤0.01%	2453
2022 Q1	–	Sell	-26	Closed	-$19K	–	2644
2021 Q4	$19K	Buy	+26	New	+$17.4K	﹤0.01%	1419
2019 Q2	–	Sell	-10	Closed	-$26K	–	2510
2019 Q1	$26K	Buy	10 +8	+400%	+$25.7K	﹤0.01%	1655
2018 Q4	$6K	Buy	+2	New	+$10.2K	﹤0.01%	2054
2018 Q2	–	Sell	-3	Closed	-$33K	–	3102
2018 Q1	$33K	Buy	+3	New	+$80.3K	﹤0.01%	2537
2017 Q4	–	Hold	0	–	–	–	1657
2017 Q3	–	Hold	0	–	-$23K	–	1286
2017 Q2	–	Hold	0	–	–	–	777

Other funds holding CYTO

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

SCA

Stonebridge Capital Advisors St Paul, Minnesota $1.43B AUM 21.98% 1-Year Est. Return

Two Sigma Securities's CYTO Position: Q4 2022 in Review

Two Sigma Securities sold out of Altamira Therapeutics Ltd (CYTO) in Q4 2022, closing a stake of 58 shares — an estimated $7K sold.

Two Sigma Securities first reported a position in CYTO in Q1 2018 and held it in 5 quarters. The position peaked at $33K in Q1 2018. 6 funds tracked by Wall St. Rank hold CYTO as of Q4 2022.

Two Sigma Securities reported no remaining Altamira Therapeutics Ltd position as of Q4 2022 after selling out during the quarter.
Two Sigma Securities sold 58 Altamira Therapeutics Ltd shares in Q4 2022, an estimated $7K.
Two Sigma Securities first reported a position in Altamira Therapeutics Ltd in Q1 2018 and held it in 5 quarters.
Two Sigma Securities's Altamira Therapeutics Ltd position peaked at $33K in Q1 2018.
6 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q4 2022.

Based on Two Sigma Securities's 13F filing for Q4 2022, filed 14 Feb 2023.